REQORSA
NSCLC
About Genprex
Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.
View full company profileAbout Genprex
Genprex is a clinical-stage biotech focused on developing gene therapies for cancer and diabetes using its proprietary Oncoprex® non-viral delivery platform. The company's strategy centers on advancing its lead candidate, REQORSA, through mid-stage trials in non-small cell and small cell lung cancer, with programs supported by multiple FDA Fast Track and Orphan Drug designations. While still pre-revenue, Genprex aims to address large, underserved patient populations by combining its platform technology with established therapies to overcome treatment resistance.
View full company profileTherapeutic Areas
Other NSCLC Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM7008 | Harbour BioMed | Phase 1 |
| HBM7004 | Harbour BioMed | Discovery |
| LR19125 | AVEO Oncology | Pre-clinical |